The human epidermal growth factor receptors 2, 3, and 4 (HER2, HER3, and HER4, respectively) are frequently overexpressed in many human cancers, and therefore may be potential targets for receptor-mediated gene transfer. To evaluate this possibility, we constructed a series of HER-targeted gene transfer vehicles by covalently linking poly-L-lysine polymers (pLYS) to the epidermal growth factor-like domain of the HER ligand neuregulin-1 (NRG1 177-244 ), a HER2 antibody (Ab), and the Fab fragment of the HER2 Ab. In vitro, pLYS modification of NRG1 177-244 decreased the affinity of the ligand for HER3 or HER4 homodimer receptors by 6-to 7-fold. DNA loading of the pLYS-modified NRG1 177-244 had a minimal additional affect on the affinity of the complex for its receptor. In cell lines engineered to solely express HER2, HER3, or HER4, each vehicle correctly targeted the receptors; the NRG1 177-244 construct transferred a luciferase gene only into cells expressing HER4, whereas the HER2 Ab and Fab constructs transferred the reporter gene only into cells expressing HER2. The most efficient gene transfer occurred using the intact HER2 Ab as a gene transfer vehicle, whereas the Fab fragment of the HER2 Ab was the least efficient, and NRG1 177-244 was intermediate. These studies suggest that the NRG receptor or HER2, a component of the receptor, can be pursued as targets for gene transfer.
S
elective gene transfer to cancer cells is a barrier to the implementation of gene therapy as a cancer treatment strategy. Receptor-mediated gene transfer is one method that may have the potential to achieve the necessary selectivity. Reports of targeting the transferrin receptor, 1 asialooromucoid, 2 folate, 3 the polymeric immunoglobulin (Ig) receptor, 4 and the epidermal growth factor receptor (EGFR) 5 have shown the feasibility of such an approach. Recently, we demonstrated that a member of the human epidermal growth factor receptor (HER) family, HER2, could also be used as a target for receptor-mediated gene transfer using an antibody (Ab) directed against HER2 as a gene transfer agent. 6 The HER proteins are growth factor receptors with intrinsic tyrosine kinase activity, termed subclass 1 growth factor receptors. Members of the family include EGFR, HER2 (ErbB-2), HER3 (ErbB-3), and HER4 (ErbB-4). 7 This family of receptors has been implicated in the pathogenesis of many human tumors. Overexpression of HER2 due to gene amplification is involved in the transformation of breast, 8 -10 ovary, 9 lung, 11 and gastric epithelial cells. In addition, patients whose tumors overexpress HER2 have a poor prognosis, 9, 12 with shorter overall survival compared with patients whose tumors do not express HER2. Less is known about the function and clinical importance of HER3 and HER4. Increased HER3 expression has been reported in a subset of human mammary, pancreatic, prostate, and oral cancers. [13] [14] [15] HER3 also enhances the transforming activity of HER2 when coexpressed in NIH3T3 cells. 16, 17 HER4 is expressed in several established tumor cell lines, 18 but little is known about its expression in primary tumor cells.
There are a number of different peptides that bind and activate these receptors, as the receptor proteins are modular, with homo-or heterodimerization possible within the family. Each combination, however, alters ligand binding specificity. EGF, transforming growth factor-␣, amphiregulin, betacellulin, and epiregulin bind EGFR homodimers. 19 HER2/HER3 heterodimers bind neuregulin 1 (NRG1) (also called heregulin-␤1). HER3 homodimers bind NRG1 and also the recently described NRG2. 20, 21 HER4 homodimers can bind NRG1, NRG2, 14, 15 betacellulin, epiregulin, HB-EGF, and a third member of the NRG family, NRG3. This report focuses on NRG1 and HER2. The functional effect of the interaction of NRG1 with its receptor(s) is not completely understood, but appears to be tissue-specific and can be classified into three broad categories. Receptor activation regulates neuron-Schwann cell interactions, notably Schwann cell differentiation and proliferation. 22, 23 It also regulates neuron-muscle cell interactions in the differentiation of neuromuscular synapses, 24 activation of synapse-specific gene expression, 25 and expression of ion channels in skeletal muscle. 26 Finally, receptor activation also causes epithelial cell differentiation and proliferation. [27] [28] [29] [30] [31] [32] Because of the preferential expression of these receptor proteins in certain tumors, therapy directed to HER2-, HER3-, or HER4-expressing cancers may be possible using NRGs or receptor-specific Abs. NRG1, the first member of the NRG family, exists in its mature form as a 45-kDa protein derived by the proteolytic cleavage of a 645-amino acid (aa) precursor in the endoplasmic reticulum or at the cell surface. 33 Structurally it is a multimotif protein containing an IgG domain, a carbohydrate spacer, an EGF-like domain, and a juxtamembrane region. 34 Receptor binding is mediated through a specific 67-aa motif in the protein, called the EGF-like domain. This domain interacts with low-affinity binding sites formed by HER3 or HER4 homodimers and high-affinity sites formed by HER2/HER3 and HER2/HER4 heterodimers. We hypothesized that a minimal NRG1 ligand consisting of the 67-aa EGF-like domain (NRG1 177-244 ) could be derivatized to form an effective gene transfer complex, thereby targeting tumors expressing HER3/HER3 or HER4/HER4 homodimers and HER2/HER3 or HER2/HER4 heterodimers. In addition, because stimulation and internalization of the receptor/NRG1 177-244 gene transfer complex would occur through a normal physiologic process, NRG1 177-244 would be a more efficient gene transfer agent than Abs targeting the receptor. Here we describe the development of the minimal NRG1 ligand as a gene transfer vehicle, and directly compare Ab-mediated gene transfer directed against HER2 with ligand-mediated gene transfer using NRG1 binding sites.
MATERIALS AND METHODS

Cell culture
The human breast adenocarcinoma cell lines BT474, SKBR-3, MCF-7, and MDA-MB-468; the ovarian carcinoma cell line CaOV3; and the human erythroleukemia cell line K562 were obtained from the American Type Culture Collection (Manassas, Va). All cell lines were maintained in Ham's F-12 medium and Dulbecco's modified Eagle's medium (1:1) containing 10% fetal bovine serum, 0.5 mM L-glutamine, 100 U/mL penicillin, and 100 g/mL streptomycin. The K562-related cell lines K562.HER2, K562.HER3, and K562.HER4 were produced through the stable transfection of K562 cells with the appropriate full-length HER cDNA under the control of the cytomegalovirus promoter. The transfected plasmid contained the aminoglycoside phosphotransferase gene, 35 or this gene was present on a second plasmid (pCDNA3, Invitrogen, Carlsbad, Calif) and cotransfected with the HER cDNAs. The HER transfectants were grown in the same culture medium as the parent, but also containing 750 g/mL G418.
Preparation of poly-L-lysine DNA complexes
The humanized HER2 Ab (rhuMAbHER2), 36 the Fab of this Ab (rhuMAbHER2.Fab), 37 and the EGF-like domain of NRG1 (NRG1 177-244 ) 38 have been described previously. Poly-L-lysine polymers (pLYS) of different chain lengths (158 and 251 lysines) were obtained from Sigma (St. Louis, Mo). Chemical conjugation was performed by resuspending the targeting protein (rhuMAbHER2, rhuMAbHER2.Fab, NRG1 177-244 ) in 1 mL of 0.1 M 2-(N-morpholino)ethanesulfonic acid (pH 5.0), a 10-fold excess of the desired pLYS polymer, and a 500-fold excess of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (Pierce, Rockford, Ill). The reaction mix was incubated at room temperature overnight. Underivatized protein was separated from the reaction mixture by cation exchange chromatography. The reaction mixture was adjusted to a pH of 8.5 using 20 mM of sodium borate and loaded onto an S Sepharose Fast Flow column; next, 1-mL fractions were collected over a 30-minute gradient (buffer A ϭ 20 mM of sodium borate (pH 8.5); buffer B ϭ buffer A plus 4 M NaCl). Further purification of derivatized rhuMAbHER2 included removing unbound pLYS by centrifugation through a Centriprep-100 filter/concentrator (Amicon, Beverly, Mass) to yield pLYS-rhuMAbHER2. Purification of derivatized rhuMAbHER2.Fab and NRG1 177-244 required reversed-phase high performance liquid chromatography (HPLC) to remove unbound pLYS. Fractions with 280 nm absorbance obtained by cation exchange chromatography were combined, adjusted to 0.1% trifluoroacetic acid, and loaded onto a C-18 reversed phase column (SynChropak RP-P, Synchrom, Lafeyette, Ind). Fractions (1 mL) were collected over a 30-minute gradient (buffer A ϭ 0.1% trifluoroacetic acid; buffer B ϭ buffer A plus 100% acetonitrile). The eluant was monitored at 280 nm and peaks were pooled, lyophilized, and resuspended in water. Protein concentration was determined by bicinchoninic acid assay (Pierce). Amino acid analysis was performed to determine the molar ratio of carrier to pLYS. Samples were hydrolyzed in 5.7 N HCl for 24 hours at 110°C and analyzed using a Beckman 6300 Amino Acid Analyzer (Beckman Instruments, Fullerton, Calif).
DNA binding of poly-L-lysine protein conjugates
To create the DNA complex, pLYS-conjugated proteins were mixed with DNA at room temperature in N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (HEPES)-buffered saline (HBS) (15 mM HEPES, 150 mM NaCl) and allowed to incubate for 15 minutes. The ability of the poly-L-lysine conjugate to bind DNA was tested by electrophoretic mobility through a 1% agarose gel containing ethidium bromide (EB). Plasmid DNA (1 g) was incubated for 15 minutes in HBS at room temperature with varying amounts of pLYS-carrier conjugate. Samples were loaded onto the gel, and electrophoresis was performed at 50 V for 2 hours. The mass ratio of pLYS-carrier to DNA at which complete retardation of DNA gel mobility was calculated and the ratio of pLYS-carrier conjugate to DNA were used for all subsequent receptor competition assays and gene transduction experiments.
Plasmid preparation
The plasmids pRSVluc, which encodes the luciferase gene driven by the Rous sarcoma virus promoter, and pCH110 (Pharmacia, Piscataway, NJ), which encodes the ␤-galactosidase gene driven by the simian virus 40 late promoter, were purified from transfected Escherichia coli (HB101) using the Wizard Maxipreps system (Promega, Madison, Wis). The recovered DNA was further purified by ultracentrifugation over a CsCl cushion. CsCl (5 mL, 1.1673 g/mL, refractive index ϭ 1.4137) and EB (100 L, Sigma, 10 g/mL) were added to the DNA, and the solution was transferred to Quick Seal tubes (Beckman). The sealed tubes were centrifuged for 5 hours at 55,000 revolutions per minute, the plasmid band was harvested, and the ultracentrifugation over CsCl was repeated. After the second ultracentrifugation, the harvested plasmid was extracted three to five times with tris(hydroxymethyl)aminomethane/NaCl-saturated isopropanol, and the DNA was precipitated from ethanol at Ϫ20°C. The plasmid was recovered by centrifugation, air dried, and resuspended in 1 mL tris(hydroxymethyl)aminomethane. The concentration and purity of the DNA were assessed spectrophotometrically. Plasmid identity was confirmed by restriction endonuclease digestion.
Receptor-mediated gene transfer
Cells (5 ϫ 10 5 ) were seeded onto six-well cell culture plates (Costar, Cambridge, Mass) and allowed to adhere overnight in the appropriate growth medium. The cells were washed once with serum-free medium, and the medium was replaced with Opti-Mem (2 mL, Life Technologies, Gaithersburg, Md) or serum-free medium. pLYS-carrier-DNA complexes were then added to the appropriate wells in 500 L of HBS, and chloroquine was added to a final concentration of 100 M. After 4 hours, the media was aspirated and replaced with media supplemented with 10% fetal bovine serum. Controls included transfection using plasmid alone or lipofectamine (Life Technologies) according the manufacturer's directions.
Cells transfected with pRSVluc were analyzed using a luciferase assay (Promega), and relative light output was measured on a luminometer. Cells transfected with the lacZ gene were fixed with 1.8% formaldehyde and 2% glutaraldehyde for 5 minutes at 4°C. Next, a solution of 1.0 mg/mL 5-bromo-4-chloro-3-indonyl-␤-galactopyranoside (Boehringer Mannheim, Indianapolis, Ind) in phosphate-buffered saline (PBS) (pH 7.8) was added to each well. The cells were incubated for 16 hours at 37°C without CO 2 . For each well, the percentage of cells with blue-stained nuclei was determined by counting 500 cells by light microscopy.
Competitive receptor binding assays
Nunc-ImmunoBreakapart plates (Nalge Nunc International, Rochester, NY) were coated with 100 L of a 1/200 dilution of goat anti-human Ab (Boehringer Mannheim) in 50 mM of carbonate buffer (pH 9.6) at 4°C. The wells were washed twice with 0.05% Tween-20 in PBS and blocked with 1% bovine serum albumin in PBS for 30 minutes at 4°C. The blocking solution was removed, and 20 ng of a HER2 or HER3 IgG in 100 L of blocking buffer was added to each well. After 1 hour of shaking at room temperature, the wells were washed three times with 0.05% Tween-20 in PBS. Binding analysis was performed using serial 2-fold dilutions of NRG1 177-244 (640 -1.25 nM) in 50 L of binding buffer. Relative binding constants for the pLYS conjugates were determined using log dilutions of the pLYS conjugates or pLYS conjugate-DNA complexes in the binding reaction. A total of 100,000 cpm of 125 I-NRG1 177-244 (500 pM) were added to each well in binding buffer. The reaction was incubated at room temperature for 2 hours, and the wells were aspirated and washed three times with 0.05% Tween-20 in PBS. The individual wells were broken off, and ␥ counting was performed. All dilutions were analyzed in triplicate. Scatchard analysis was performed by the method of Munson and Robard.
RESULTS
Production and purification of rhuMAbHER2, rhuMAbHER2.Fab, and NRG1 177-244 -poly-L-lysine conjugates We used a humanized recombinant HER2 Ab (rhuMAbHER2), 36 its Fab product (rhuMAbHER2.Fab), 37 or the EGF-like domain of NRG1 (NRG1 177-244 ) 38 as the basis for our gene transfer vehicles. These agents allowed us to characterize the utility of targeting the HER2 molecule in a monovalent versus bivalent fashion (rhuMAbHER2.Fab versus rhuMAbHER2) or NRG1 binding sites (HER3 homodimers, HER4 homodimers, and HER2/HER3 or HER2/HER4 heterodimers). Poly-L-lysine (pLYS) polymers of 158 or 251 lysines (with a molecular weight of 36,600 and 52,400, respectively) were covalently linked to the Ab, Ab fragment, or minimal ligand using carbodiimide chemistry 39 to produce pLYS-rhuMAbHER2, pLYS-rhuMAbHER2.Fab, and pLYS-NRG1 177-244 . Purification of pLYS-NRG1 177-244 was accomplished by cation exchange chromatography and reversed-phase HPLC (C-18 column). Amino acid analysis of the isolated product confirmed successful pLYS conjugation (Table 1) . Furthermore, the analysis allowed us to calculate the average pLYS: carrier stoichiometry. Conjugates with polymer lengths of both 158 lysines (36,600 Da), and 251 lysines (52,400 Da) were examined, and the average pLYS:NRG1 complex stoichiometry was determined by comparing the number of lysine residues found by amino acid analysis, after subtracting the native lysine content of NRG1 177-244 from the conjugated lysine polymer length. For pLYS-NRG1 177-244 , a ratio of 0.7-0.8:1 was found. pLYS-conjugated rhuMAbHER2.Fab was also purified by cation exchange chromatography, followed by reversed-phase HPLC (C18 column). Amino acid analysis again confirmed pLYS conjugation, with an average pLYS polymer to Fab stoichiometry of 1.1:1 (Table 1) .
pLYS-conjugated rhuMAbHER2 was purified by cation exchange chromatography, followed by ultrafiltration, taking advantage of the large differences in molecular weights to separate free pLYS from pLYSrhuMAbHER2. Amino acid analysis confirmed pLYS conjugation, with an average pLYS polymer to Ab stoichiometry of 6:1 ( Table 1) .
Binding of pLYS-NRG (177-244) to HER3 and HER4 IgG
The covalent binding of pLYS to the NRG1 minimal peptide had the potential to disrupt important features in the peptide necessary for receptor interaction. Our previous studies showed that pLYS conjugation to the HER2 Ab did not affect the ability of the Ab to bind HER2. 6 To probe the effect of pLYS conjugation on the interaction of NRG1 177-244 with its receptor, we performed in vitro competitive binding assays, with the pLYS-NRG1 177-244 conjugates competing with 125 I-NRG1 177-244 for binding to HER3-IgG and HER4-IgG fusion proteins. These receptor fusion proteins consist of the extracellular domain of HER3 or HER4 fused to the Fc portion of IgG, and are expressed as homodimers. The fusion proteins closely reflect in vivo HER3 and HER4 homodimer receptors (low-affinity NRG1 receptors). As shown in Table 2 , NRG1 177-244 bound the HER3/HER3 and HER4/HER4 fusion proteins in vitro with a K d similar to that found in vivo. 40, 41 The K d for pLYS 36.6 -NRG1 177-244 binding to the HER3 fusion protein was 6-to 7-fold higher than that observed for NRG1 . Binding of pLYS 36.6 -NRG1 177-244 to the HER4 fusion protein occurred with a K d that was 13-to 14-fold higher than NRG1 177-244 . pLYS alone did not displace NRG1 177-244 binding to either the HER3 or HER4 fusion proteins when tested at concentrations of Յ10 M. Therefore, all receptor binding specificity occurs through NRG1 177-244 and not through nonspecific binding from pLYS.
Loading of the carrier with plasmid DNA results in a complex of ϳ2,000,000 Da and may profoundly effect the ability of the complex to interact with the receptor. To address this concern, competitive binding assays were repeated using DNA-loaded pLYS 36.6 -NRG1 177-244 . As shown in Table 2 , loading pLYS 36.6 -NRG1 177-244 with DNA did not change its apparent binding affinity in comparison with the carrier without DNA. However, the K d was still increased 7-fold from the underivatized ligand (NRG1 177-244 ) ( Table 2) . pLYS 36.6 -NRG1 (177-244)-DNA retained its ability to activate the receptor complex in vivo (Fig 1) , further evidence that pLYS conjugation did not disrupt its receptor binding characteristics. Exposing the breast adenocarcinoma cell line MCF-7 to pLYS-NRG1 177-244 -DNA resulted in increased receptor tyrosine phosphorylation content (Fig  1) . NRG1 177-244 increased p185 phosphotyrosine (HER2 or HER3) content at 8 minutes (Fig 1, lane 6) . The pLYS 36.6 -NRG1 177-244 -DNA also induced phosphotyrosine changes (Fig 1, lanes 2 and 3) , whereas DNA or pLYS alone did not. The changes in phosphotyrosine content were quantitatively less with the pLYS 36.6 -NRG1 177-244 -DNA complex than with NRG1 177-244 , even though identical molar amounts of NRG1 177-244 and pLYS 36.6 -NRG1 177-244 -DNA were used. However, considering the 6-to 7-fold difference in their respective K d s for the HER, the absolute difference becomes less apparent. Thus, pLYS conjugation reduced the affinity of the ligand for its receptor; however, the new K d was acceptable for use as a targeting molecule, all target specificity was derived from the NRG1 177-244 moiety, and DNA loading did not appear to interfere with the ability of the ligand to interact with the receptor either in vitro or in vivo. To further define the specificity of the pLYS 36.6 -NRG1 177-244 -directed gene transfer for the HER receptor family, NRG1 binding sites on the breast adenocarcinoma cell line SKBR3 were saturated before gene transfer with a 50-fold higher concentration of NRG1 177-244 than was present in the pLYS 36.6 -NRG1 177-244 -DNA complex. As shown in Figure 2 , saturation of NRG1 177-244 binding sites resulted in a Ͼ90% reduction in luciferase activity. The efficiency of gene transfer was measured in the SKBR3 cell line with the pLYS 36.6 -NRG1 177-244 conjugate used to transfer a lacZ expression construct. After 48 hours, the cells were fixed and stained with 5-bromo-4-chloro-3-indonyl-␤-galactopyranoside. ␤-galactosidase activity was identified in 46% of the cells. Two classes of cellular expression were evident; (a) low-level localized cytoplasmic expression, present in the majority of cells, and (b) high-level diffuse expression, resulting in whole cell staining, present in a minority of cells.
Next, pLYS 36.6 -NRG1 177-244 -directed gene transfer was generalized to HER-expressing cell lines derived from human tumors. A series of adenocarcinoma cell lines derived from human breast cancers and an ovarian cancer were used to test pLYS 36.6 -NRG1 177-244 -directed gene transfer (Table 5) . pLYS 36.6 -NRG1 177-244 was capable of directing gene transfer in each of these cell lines. Surprisingly, the degree of gene transfer did not correlate with the number of NRG1 177-244 binding sites as defined by whole cell competitive receptor binding assays using 125 I-NRG1 177-244 . This implies that the limitation to gene transfer in these cell lines is not related to receptor density or ligand/receptor binding.
Comparison of pLYS 36.6 -NRG1 177-244 , pLYS 52.4 -rhuMAbHER2.Fab, and pLYS 52.4 -rhuMAbHER2 as gene transfer agents The three gene transfer vehicles, pLYS 36.6 -NRG1 (177-244), pLYS 52.4 -rhuMAbHER2.Fab, and pLYS 52.4 -rhuMAbHER2, were directly compared to determine their relative gene transfer abilities. Equimolar amounts of DNA were transferred into the breast adenocarcinoma cell line SKBR3. Of the three gene transfer agents, pLYS 52.4 -rhuMAbHER2 was the most effective in this cell line (Fig 3) . pLYS 52.4 -rhuMAbHER2.Fab was less efficient for the same target. The reason for the difference in gene transfer efficiency between the IgG and its Fab is not clear. pLYS 36.6 -NRG1 177-244 was intermediate in its gene transfer ability when compared with pLYS 52.4 -rhuMAbHER2 and pLYS 52.4 -rhuMAbHER2.Fab. Finally, HER2-targeted or NRG1 binding site-targeted gene transfer was more efficient than liposome-mediated gene transfer.
DISCUSSION
A variety of strategies targeting human tumor cells that exhibit increased HER2 expression have recently been described, all of which may have therapeutic potential. [42] [43] [44] [45] [46] [47] [48] Our studies expand the potential HER-targeting strategies and begin to define important requirements for successful receptor-mediated gene transfer. One goal of these studies was the analysis of a NRG1 minimal ligand, NRG1 177-244 , as a gene transfer vehicle. The EGF-like domain of NRG1 177-244 clearly provided HER-specific targeting for gene transfer. Even with extensive changes made to the ligand through the covalent binding of pLYS and DNA loading, there was surprisingly little change in the apparent binding affinity of pLYS-NRG1 177-244 to the low-affinity HER3 and HER4 homodimer receptors in comparison with NRG1 177-244 . In addition, the modified ligand could still bind and activate its receptor in vivo. Thus, NRG1 residues critical for receptor binding must not be involved in the covalent modification that occurs with pLYS binding. This finding is supported by recent data from Barbacci et al, 49 who found that a region of NRG1 consisting only of amino acids 177-226 was sufficient for both receptor binding and activation in SKBR3 cells. Within this domain, the amino acids 177-181 (SHLVK) provided all of the specificity for binding to the expressed NRG1 receptor. Because these five amino acids lack free carboxyl groups, pLYS conjugation cannot occur in this region using the carbodiimide chemistry Figure 2 . Specificity of pLYS 36.6 -NRG1 177-244 -directed gene transfer. A total of 500,000 SKBR3 cells were subjected to pLYS 36.6 -NRG1 177-244 -directed gene transfer performed under standard conditions with the luciferase reporter construct pRSVluc. In the NRG1 pre-exposed condition, NRG1 binding sites were first saturated with 50-fold more NRG1 177-244 than present in the pLYS 36.6 -NRG1 177-244 complex. Cells were harvested and lysed after 48 hours, and a luciferase assay was performed. Results are representative of two experiments. 36 .6 ϭ 36,600 Da) or the 369,600-Da full-length Ab vehicle (rhuMabHER2 ϭ 150,000 Da, 6 pLYS 36.6 ϭ 219,600 Da). Such a strategy may be possible with other ligands, making it unnecessary to use the full-length protein as a targeting agent. Reduction in the size of the gene transfer complex has the theoretical advantage of increased tissue penetration and accessibility. 50 Although the gene transfer vehicle can be reduced, the bulk of the complex mass is due to bound DNA. It is not clear whether further reduction in complex size through the use of minimal DNA sequences will be effective.
Internalization of the ligand/receptor or Ab/receptor complex is critical for successful intracellular delivery of the conjugated DNA. Baulida et al 51 have recently studied the internalization rates of the HER family and have concluded that the receptors are internalization impaired. In their studies, wild-type HER4 after ligand binding did not mediate rapid ligand internalization, receptor degradation was not seen, and the receptor failed to form association complexes with clathrin-associated protein complex. EGF-responsive chimeric receptors containing the EGFR extracellular domain and HER2, HER3, and HER4 cytoplasmic domains were also studied. These chimeric receptors also had impaired ligand-induced internalization, receptor degradation, and associated protein-2 association. The observed internalization rate constant, K e , was 0.04 for chimeric HER2, HER3, and HER4 receptors and 0.07 for the native HER4 receptor in comparison with 0.13 for wild-type EGFR. This low internalization rate implies only a constitutive basal level of ligand-induced receptor endocytosis, which might suggest that the HER system is not an optimal gene transfer target. However, NRG1 is internalized and rapidly transported to the nucleus after receptor binding. 52 In addition, our studies identified gene transfer into HER2-expressing cells with Ab-based carriers and into HER2/HER3-and HER4-expressing cells using the minimal ligand. We did not see gene transfer into HER3-expressing cells in vitro. The reason for this is not clear. Efficient internalization of EGFR is thought to involve the phosphorylation of Ser 1046 -Ser 1047 , residues that are not retained in HER3. In addition, lack of ligand-induced auto-or trans-phosphorylation of the carboxyl terminus of the receptor due to the inactive tyrosine kinase domain of HER3 may also play a role in poor receptor internalization, and the low gene transfer efficiency in our engineered cell lines despite effective HER3 targeting in vitro.
In comparing the gene transfer vehicles, the pLYS-NRG1 177-244 conjugates appear to be lower in gene transfer ability relative to a full-length HER2 Ab. This difference may reflect the higher number of HER2 receptors than NRG1 binding sites in the test cell lines. However, the gene transfer efficiency of rhuMAbHER2.Fab was lower than NRG1 , suggesting that other factors, such as bivalency or receptor heterodimerization, must also be considered. The amount of DNA bound to the respective gene transfer vehicles may also differ. pLYS-rhuMAbHER2 has six pLYS polymers, compared with one on pLYSrhuMAbHER2.Fab; therefore, pLYS-rhuMAbHER2 may be capable of binding more DNA. This cannot be the sole explanation for differences in gene transfer, however, as pLYS-NRG1 177-244 has a pLYS content similar to pLYS-rhuMAbHER2.Fab but has better gene transfer abilities.
Other strategies have also been used to target NRG1 binding sites. NRG1-directed retroviral targeting 53 and NRG1 toxin fusion proteins 54 have been described previously. Although effective, potential drawbacks to these techniques as currently used are low retroviral titers, systemic toxicity of preformed toxins, and the immunogenicity of the reagents. Receptor-mediated gene transfer may avoid some of these issues. The use of a native ligand should minimize immunogenicity. However, the pLYS polymer and the new polymer-ligand covalent bond created in the chemical synthesis are not native and may prove to be immunogenic. Use of a native ligand was also raises new issues. For example, the effect of pLYS-NRG1 177-244 -induced activation of its receptor is not known. With further structural information, the elimination of domains resulting in receptor activation may be possible.
The properties of the NRG1-mediated gene transfer system make it a promising form of targeted gene delivery. The strategy is very flexible and can target different members of the receptor family: HER2 by using rhuMAbHER2 or rhuMAbHER2.Fab, and NRG1 binding sites by using NRG1. Thus, any cell expressing a relatively tumor-specific HER family member could be targeted. [7] [8] [9] [10] [11] [12] Finally, with more detailed knowledge of the NRG1 EGF-like domain binding determinants, 49 it may be possible to construct "biregulin" carriers to target tumors expressing any subclass I receptor tyrosine kinase or tailor the molecule to identify only HER3, HER4, or HER2 binding sites or reduce the targeting molecules to even smaller sizes. We are currently investigating other HER Abs and NRG peptides to identify the optimal targeting vehicle.
